Anzeige
Mehr »
Login
Mittwoch, 28.02.2024 Börsentäglich über 12.000 News von 684 internationalen Medien
Feuerwerk fürs Depot: Rohstoff-Geheimtipp! Startet JETZT der Kursturbo?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A1J84E | ISIN: US00287Y1091 | Ticker-Symbol: 4AB
Tradegate
28.02.24
12:58 Uhr
165,40 Euro
+0,30
+0,18 %
Branche
Pharma
Aktienmarkt
S&P 100
S&P 500
1-Jahres-Chart
ABBVIE INC Chart 1 Jahr
5-Tage-Chart
ABBVIE INC 5-Tage-Chart
RealtimeGeldBriefZeit
165,60166,1013:34
165,50166,6013:34

Aktuelle News zur ABBVIE Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
12:58AbbVie inks $713m deal for OSE chronic inflammation drug2
12:26Revolution via resolution: AbbVie pays $48M for OSE's preclinical chronic inflammation drug2
08:12AbbVie partners with OSE Immunotherapeutics to develop novel nonoclonal antibody5
07:48OSE Immunotherapeutics to Host a Live Webcast to Discuss AbbVie Global Partnership302On February 28, 2024, at 6:00 p.m. CET 12:00 a.m. ET. Regulatory News: OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE),will host a live webcast on February 28, 2024, at 6:00 p.m....
► Artikel lesen
07:36AbbVie and OSE Immunotherapeutics Announce Partnership to Develop a Novel Monoclonal Antibody for the Treatment of Chronic Inflammation202Global license and collaboration agreement to focus on the development of OSE-230, a monoclonal antibody designed to resolve chronic inflammation OSE Immunotherapeutics to receive an upfront...
► Artikel lesen
06:54AbbVie To Receive Global License To Develop OSE-230 From OSE Immunotherapeutics233BRUSSELS/FRANKFURT/PARIS (dpa-AFX) - AbbVie Inc. (ABBV) and OSE Immunotherapeutics SA announced a strategic partnership to develop OSE-230, a monoclonal antibody designed to resolve chronic...
► Artikel lesen
06:05AbbVie and OSE Immunotherapeutics Announce Partnership to Develop a Novel Monoclonal Antibody for the Treatment of Chronic Inflammation41- Global license and collaboration agreement to focus on the development of OSE-230, a monoclonal antibody designed to resolve chronic inflammation - OSE Immunotherapeutics to receive an upfront...
► Artikel lesen
DiAbbVie/ Genmab win FDA priority review for lymphoma therapy5
FrPharma Stock Roundup: Pfizer's Velsipity Receives EU Nod, ABBV Gets New CEO & More28
FrAbbVie and Tentarix partner to develop oncology and immunology biologics3
FrAbbVie's Skyrizi shows promise as personalised treatment for psoriasis13
FrAbbVie and Tentarix enter biologic development deal4
DoAbbVie, Tenatrix team up for immunology, oncology drug discovery4
DoAbbVie Selling $15 Billion Bonds to Buy ImmunoGen, Cerevel11
DoAbbVie & Tentarix Partner on Conditionally-Active Biologics for Oncology & Immunology2
DoAbbVie Taps Robert Michael as Chief Executive Officer4
DoAbbVie wraps up $64M oncology, immunology deal with Tentarix5
DoAbbVie Teams Up With Tentarix To Develop Multi-specific Biologics For Oncology, Immunology336WASHINGTON (dpa-AFX) - Drug manufacturer AbbVie Inc. (ABBV) announced a collaboration with Tentarix Biotherapeutics on Thursday to use the latter's Tentacles platform for developing conditionally...
► Artikel lesen
DoAbbVie partners with Tentarix on biologic therapies3
DoAbbVie's Produodopa rolled out by NHS England for advanced Parkinson's patients4
Seite:  Weiter >>
518 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,2,19